Table 1 Distribution of patients in the study
From: The optimal use of PEG-Asparaginase in relapsed ALL—lessons from the ALLR3 Clinical Trial
PEG-ASNase | None | Assayed patients | ||||
|---|---|---|---|---|---|---|
n | 354 | % | 16 | % | 33 | % |
Sex | ||||||
Male | 224 | 63.3 | 9 | 56.3 | 24 | 72.7 |
Female | 130 | 36.7 | 7 | 43.8 | 9 | 27.3 |
Age at first relapse (years) | ||||||
Median (IQR) | 9.3 (6.9–13.3) | 8.3 (5.9–11.3) | 8.6 (7–11.4) | |||
<10 | 193 | 54.5 | 11 | 68.8 | 24 | 72.0 |
⩾10 | 161 | 45.5 | 5 | 31.3 | 9 | 27.3 |
Immunophenotype | ||||||
B cell | 302 | 85.3 | 14 | 87.5 | 27 | 81.2 |
T cell | 52 | 14.7 | 2 | 12.5 | 6 | 18.2 |
Time to relapse (months) | ||||||
Median (IQR) | 39 (25–55) | 30 (19–42.5) | 34 (18–48) | |||
Very early | 46 | 13.0 | 4 | 25.0 | 8 | 24.2 |
Early | 117 | 33.1 | 7 | 43.8 | 10 | 30.3 |
Late | 191 | 54.0 | 5 | 31.3 | 15 | 45.5 |
Site of relapse | ||||||
Isolated extramedullary | 89 | 25.1 | 0 | 0.0 | 14 | 42.4 |
Isolated marrow | 205 | 57.9 | 11 | 68.8 | 15 | 45.5 |
Combined | 60 | 16.9 | 5 | 31.3 | 2 | 6.1 |
Risk group | ||||||
Standard | 21 | 5.9 | 0 | 0.0 | 3 | 9.1 |
Intermediate | 234 | 66.1 | 8 | 50.0 | 17 | 51.5 |
High | 99 | 28.0 | 8 | 50.0 | 13 | 39.4 |
Cytogenetics | ||||||
High hyperdiploid | 54 | 15.3 | 6 | 37.5 | 8 | 24.2 |
ETV6-RUNX1 | 37 | 10.5 | 1 | 6.3 | 2 | 6.1 |
Intermediate | 68 | 19.2 | 3 | 18.8 | 10 | 30.3 |
Poor | 39 | 11.0 | 3 | 18.8 | 1 | 3.0 |
Unknown | 156 | 44.1 | 1 | 6.3 | 12 | 36.4 |
Outcome | ||||||
Alive and well | 184 | 52.0 | 7 | 43.8 | 16 | 48.5 |
Refractory to treatment | 25 | 7.1 | 3 | 18.8 | 2 | 6.1 |
Second relapse | 74 | 20.9 | 3 | 18.8 | 4 | 12.1 |
Disease-related death | 10 | 2.8 | 0 | 0.0 | 0 | 0.0 |
Treatment-related death | 40 | 11.3 | 2 | 12.5 | 6 | 18.2 |
Withdrawn | 19 | 5.4 | 0 | 0.0 | 4 | 12.1 |
Lost to followup | 1 | <1 | 0 | 0.0 | 0 | 0.0 |
Second malignancy | 1 | <1 | 1 | 6.3 | 1 | 3.0 |
